Frontiers in Medicine (Apr 2022)
Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review
- Michele Balma,
- Virginia Liberini,
- Virginia Liberini,
- Manuela Racca,
- Riccardo Laudicella,
- Riccardo Laudicella,
- Riccardo Laudicella,
- Matteo Bauckneht,
- Matteo Bauckneht,
- Ambra Buschiazzo,
- Daniele Giovanni Nicolotti,
- Simona Peano,
- Andrea Bianchi,
- Giovanni Albano,
- Natale Quartuccio,
- Ronan Abgral,
- Silvia Daniela Morbelli,
- Silvia Daniela Morbelli,
- Calogero D'Alessandria,
- Enzo Terreno,
- Martin William Huellner,
- Alberto Papaleo,
- Désirée Deandreis
Affiliations
- Michele Balma
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
- Virginia Liberini
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
- Virginia Liberini
- Division of Nuclear Medicine, Department of Medical Science, University of Turin, Turin, Italy
- Manuela Racca
- Nuclear Medicine Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
- Riccardo Laudicella
- Department of Biomedical and Dental Sciences and of Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, Italy
- Riccardo Laudicella
- Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland
- Riccardo Laudicella
- Nuclear Medicine Unit, Fondazione Istituto G. Giglio, Cefalù, Italy
- Matteo Bauckneht
- IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- Matteo Bauckneht
- Department of Health Science (DISSAL), University of Genoa, Genoa, Italy
- Ambra Buschiazzo
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
- Daniele Giovanni Nicolotti
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
- Simona Peano
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
- Andrea Bianchi
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
- Giovanni Albano
- Nuclear Medicine Unit, Fondazione Istituto G. Giglio, Cefalù, Italy
- Natale Quartuccio
- Nuclear Medicine Unit, A.R.N.A.S. Civico di Cristina and Benfratelli Hospitals, Palermo, Italy
- Ronan Abgral
- 0Department of Nuclear Medicine, University Hospital of Brest, Brest, France
- Silvia Daniela Morbelli
- IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- Silvia Daniela Morbelli
- Department of Health Science (DISSAL), University of Genoa, Genoa, Italy
- Calogero D'Alessandria
- 1Department of Nuclear Medicine, Klinikum Rechts der Isar TU München, Munich, Germany
- Enzo Terreno
- 2Department of Molecular Biotechnology and Health Sciences, Molecular & Preclinical Imaging Centers, University of Turin, Turin, Italy
- Martin William Huellner
- Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland
- Alberto Papaleo
- Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy
- Désirée Deandreis
- Division of Nuclear Medicine, Department of Medical Science, University of Turin, Turin, Italy
- DOI
- https://doi.org/10.3389/fmed.2022.881551
- Journal volume & issue
-
Vol. 9
Abstract
Breast cancer is one of the most common malignancies in women, with high morbidity and mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine can improve the accuracy of diagnosis and staging, refine surveillance strategies and accuracy in choosing personalized treatment approaches, including radioligand therapy. Nuclear medicine thus shows great promise for improving the quality of life of breast cancer patients by allowing non-invasive assessment of the diverse and complex biological processes underlying the development of breast cancer and its evolution under therapy. This review aims to describe molecular probes currently in clinical use as well as those under investigation holding great promise for personalized medicine and precision oncology in breast cancer.
Keywords
